New Zealand markets open in 3 hours 29 minutes

CRISPR Therapeutics AG (CRSP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
54.01-1.37 (-2.47%)
At close: 04:00PM EDT
54.01 0.00 (0.00%)
After hours: 07:45PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 4.58B
Enterprise value 2.71B
Trailing P/E 124.34
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)15.99
Price/book (mrq)2.20
Enterprise value/revenue 10.03
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.77
52-week change 3-3.98%
S&P500 52-week change 322.55%
52-week high 391.10
52-week low 337.55
50-day moving average 356.63
200-day moving average 360.46

Share statistics

Avg vol (3-month) 31.34M
Avg vol (10-day) 31.41M
Shares outstanding 584.92M
Implied shares outstanding 686.83M
Float 883.37M
% held by insiders 11.86%
% held by institutions 171.15%
Shares short (14 Jun 2024) 414.87M
Short ratio (14 Jun 2024) 411.74
Short % of float (14 Jun 2024) 419.86%
Short % of shares outstanding (14 Jun 2024) 417.51%
Shares short (prior month 15 May 2024) 415.33M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -79.91%
Operating margin (ttm)-27,894.25%

Management effectiveness

Return on assets (ttm)-7.97%
Return on equity (ttm)-11.02%

Income statement

Revenue (ttm)271.71M
Revenue per share (ttm)3.40
Quarterly revenue growth (yoy)-99.50%
Gross profit (ttm)N/A
EBITDA -279.02M
Net income avi to common (ttm)-217.14M
Diluted EPS (ttm)-2.70
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.11B
Total cash per share (mrq)24.83
Total debt (mrq)234.93M
Total debt/equity (mrq)11.27%
Current ratio (mrq)17.81
Book value per share (mrq)24.56

Cash flow statement

Operating cash flow (ttm)-159.42M
Levered free cash flow (ttm)-111.89M